A Phase I, Open Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Properties of Orally Administered AT-406 in Patients with Advanced Solid Tumors and Lymphomas.

Ascenta Therapeutics, Inc

Co-Investigator

3.

2010

2012

The TEAM trial (Tasigna efficacy in advanced melanoma): A randomized, Phase III, open label, multi-center, two-arm study to compare the efficacy of TasignaÂ® versus in: CAMN107B2301 The TEAM trial (Tasigna efficacy in advanced melanoma): A randomized, Phase III, open label, multi-center, two-arm study to compare the efficacy of TasignaÂ® versu

Klee-Jenkins Utility of Serum and Tissue Biomarkers for Predicting Response to Androgen Deprivation Therapy in the Population of Men with Rising PSA Following Definitive Treatment in: SPORE in Prostate Cancer

National Cancer Institute

Co-Project Leader

16.

2011

A Randomized, Multi-Center, Placebo-Controlled Study of Mapatumumab ([HGS1012], A Fully-Human Monoclonal Antibody to Trail-R1) In Combination with Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Second-Line Therapy in Men with Castrate Resistant Prostate Cancer in: OGX-011-10: A randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Second-line Therapy in Men with Castrate Resistant Prostate Cancer.

OncoGenex Technologies.

Program Director / Principal Investigator

28.

2009

2011

A Phase 1b/2 Study of AMG 655 in Combination with Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects with Metastatic Colorectal Cancer

Amgen

Co-Investigator

29.

2009

2011

A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients With Pancreatic Cancer in: REPLACEMENT - I2I-MC-JMMC A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients With Pancreatic Cancer

Eli Lilly And Company

Co-Investigator

30.

2009

2011

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma

Phase I Safety and Tolerability Study of Figitumumab Combined with Pegvisomant in Patients with Advanced Solid Tumors

Pfizer Inc

Co-Investigator

34.

2009

2011

A Phase 1 Study of PKI-587 Administered as an Intravenous Infusion to Subjects with Solid Tumors

Wyeth Pharmaceuticals

Co-Investigator

35.

2009

2011

Schedule A in: A Phase I open label dose escalation study to evaluate the safety and tolerability of SGN-75 in patients with CD70-positive relapsed or refractory non-hodgkins lymphoma or metastatic renal cell carcinoma

Seattle Genetics, Inc.

Co-Investigator

36.

2009

2011

Schedule B in: A Phase I open label dose escalation study to evaluate the safety and tolerability of SGN-75 in patients with CD70-positive relapsed or refractory non-hodgkins lymphoma or metastatic renal cell carcinoma

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) when Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic Breast Cancer Whose Disease has Failed Prior Taxane-Based Treat

A Phase III, Randomized, Parallel Group, Multi-Center Study in the Recurrent Glioblastoma Subjects to Compare the Efficacy of AZD2171[RECENTIN] Monotherapy and the Combination of AZD2171 with Lomustine to the Efficacy of Lomustine Alone

Astra Zeneca Pharmaceuticals

Co-Investigator

41.

2008

2011

Neoadjuvant trial of lapatinib for the treatment of women with DCIS breast cancer in: Neoadjuvant trial of lapatinib for the treatment of women with DCIS breast cancer

Breast Cancer Research Foundation

Consultant

42.

2008

2011

A Phase 1/2, Multicenter, Dose Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of Th-302 in Combination with A)Gemciabine or B)Docetaxel or C) Pemetrexed in Subjects with Advanced Solid Tumors in: TH-CR-402, A Phase 1/2, Multicenter, Dose Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of Th-302 in Combination with A)Gemcitabine or B)Docetaxel or C) Pemetrexed in Subjects with Advanced Solid Tumors

A Phase IIA, Open-Label Study to Assess the Safety and Efficacy of a Single Intravenous (IV) Dose of VB-111 in: VB111 - A Phase IIA, Open-Label Study to Assess the Safety and Efficacy of a Single Intravenous (IV) Dose of VB-111 in Subjects with Advanced Differentiated Thyroid Cancer (DTC).

A Randomized Phase III Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Unresectable or Metastatic Melanoma in: H8K-MC-JZAO A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28 Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma

Randomized Phase II Study of Two Schedules of Pixantrone in Patients with MBC

Cell Therapeutics, Inc

Co-Investigator

54.

2010

REOLYSINÂ® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with SCHNC in: REO 018: Phase 3 Study of REOLYSINÂ® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with Metastatic or Recurrent SCCHN who have Progressed on or after Prior Platinum-Based Chemotherapy